- Home
- HRMY vs IMTX Comparison
HRMY vs IMTX Comparison
Compare HRMY & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRMY | IMTX |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Germany |
| Employees | N/A | 407 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | HRMY | IMTX |
|---|---|---|
| Price | $31.05 | $11.06 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $44.11 | $19.00 |
| AVG Volume (30 Days) | ★ 793.3K | 308.9K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | $25.91 |
| P/E Ratio | $12.04 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $4.22 |
| 52 Week High | $40.87 | $12.41 |
Technical Indicators
Market Signals| Indicator | HRMY | IMTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.87 | 54.52 |
| Support Level | $25.92 | $9.61 |
| Resistance Level | $30.96 | $11.41 |
| Average True Range (ATR) | 1.47 | 0.50 |
| MACD | 0.07 | -0.04 |
| Stochastic Oscillator | 35.36 | 53.39 |
Price Performance
Historical ComparisonAbout HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About IMTX Immatics N.V.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.